ReviewClinical medicine (London, England)2018
Diagnosis and treatment of severe asthma: a phenotype-based approach.
Review in Clinical medicine (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.Respiratory research · 2021Pooled it
- Self-directed de-escalation of maintenance inhaler therapy in patients with severe asthma in remission with biologic treatment: An observational study.The journal of allergy and clinical immunology. Global · 2026Article
- Age-sex differences in the global burden of asthma and risk factors, 1990-2021: results from the global burden of disease study 2021.BMC pulmonary medicine · 2026Article
- Age-Related Genetic Causal Association Between Asthma and Delirium: A Bidirectional Two-Sample Mendelian Randomization.Brain and behavior · 2026Article
- Differences in Type 2 Phenotype and Clinical Characteristics of Adult Asthma Patients with Different Severity, Across GINA Step 1 to 5 Asthma.Journal of asthma and allergy · 2026Article
- Glycolytic-Cholesterol Subtypes of Severe Asthma Reveal Distinct Immune-Inflammatory and Metabolic Phenotypes.Journal of inflammation research · 2026Article
- Prevalence and Clinical Characteristics of Severe Asthma With Fungal Sensitization in Korea.Allergy, asthma & immunology research · 2025Article
- CIAPIN1 promotes proliferation and migration of PDGF-BB-activated airway smooth muscle cells via the PI3K/AKT and JAK2/STAT3 signaling pathways.Physiological reports · 2025Article
- AI-Driven Data Analysis for Asthma Risk Prediction.Healthcare (Basel, Switzerland) · 2025Article
- Investigation of the mechanistic impact of CBL0137 on airway remodeling in asthma.BMC pulmonary medicine · 2025Article
- Status asthmaticus and the use of ketamine nebulization and magnesium sulfate: current strategies and outcomes.Annals of medicine and surgery (2012) · 2025Review
- Biologic therapies targeting type 2 cytokines are effective at improving asthma symptoms and control-a systematic review and meta-analysis.The journal of allergy and clinical immunology. Global · 2025Article
- Recent advances in research on common targets of neurological and sex hormonal influences on asthma.Clinical and translational allergy · 2025Review
- Efficacy and Safety of Omalizumab Combined with Allergen-Specific Immunotherapy in the Treatment of Moderate-to-Severe Allergic Asthma: A Prospective Cohort Study in a Chinese Population.Journal of asthma and allergy · 2025Article
- Trade-offs from a family perspective: considerations in choosing between omalizumab and complementary alternative medicine for pediatric severe asthma.Frontiers in pharmacology · 2025Review
- Article
- Epigenetic signatures of asthma: a comprehensive study of DNA methylation and clinical markers.Clinical epigenetics · 2024Article
- Knockdown of KIF23 alleviates the progression of asthma by inhibiting pyroptosis.BMJ open respiratory research · 2024Article
- Unraveling the role of NLRP3 inflammasome in allergic inflammation: implications for novel therapies.Frontiers in immunology · 2024Review
- Inhibition of long non-coding RNA NEAT1 suppressed the epithelial mesenchymal transition through the miR-204-5p/Six1 axis in asthma.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe asthma is a heterogeneous and often difficult to treat condition that results in a disproportionate cost to healthcare systems. Appropriate diagnosis and management of severe asthma is critical, as most asthma deaths have been retrospectively identified as having poorly recognised severe asthma. With multiple biologic agents becoming available, it is crucial to correctly phenotype patients in order to identify those that will respond to these high-cost treatments. We provide an overview of the assessment, phenotyping and management of severe asthma in primary and secondary care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.